Treatment of Adult Soft Tissue Sarcomas: An Overview

Overview

Journal Rare Cancers Ther

Specialty Oncology

Date 2016 May 17

PMID 27182479

Citations 12

Authors

Samia Arifi

Rhizlan Belbaraka

Rabie Rahhali

Nabil Ismaili

Affiliations

Soon will be listed here.

Abstract

Sarcomas are uncommon malignancies accounting for about 1% of all adult malignancies. Sarcomas are a heterogeneous group of tumors which includes more than 100 different subtypes. Surgery is the mainstay therapy for localized disease. In selected patients the combination of surgery with radiotherapy achieves better local control and offers the best chance of cure. Systemic treatment including cytotoxic chemotherapy or targeted therapies remains the mainstay therapy for most patients with advanced disease. There are a wide variety of clinical situations, such that an individualized treatment plan must be defined by a multidisciplinary tumor board. Treatment decisions should take into consideration the histology, site of disease, stage, performance status, treatment goals, and the patient's wishes. The management of patients should be carried out in a center with expertise in the treatment of sarcomas for optimal outcome. This review will cover the different treatment modalities of adult soft tissue sarcomas.

Citing Articles

Establishment and characterization of 18 Sarcoma Cell Lines: Unraveling the Molecular Mechanisms of Doxorubicin Resistance in Sarcoma Cell Lines.

Cho Y, Kim S, Kim H, Han I, Ku J J Transl Med. 2024; 22(1):889.

PMID: 39358756 PMC: 11445991. DOI: 10.1186/s12967-024-05700-y.

Unplanned Resections of Soft Tissue Sarcomas-Necessity of Re-Resection?.

Fromm J, Klein A, Mentrup F, Lindner L, Nachbichler S, Holzapfel B Cancers (Basel). 2024; 16(10).

PMID: 38791930 PMC: 11120091. DOI: 10.3390/cancers16101851.

The Effect of chemo- and radiotherapy on tumor necrosis in soft tissue sarcoma- does it influence prognosis?.

Fromm J, Klein A, Kirilova M, Lindner L, Nachbichler S, Holzapfel B BMC Cancer. 2024; 24(1):303.

PMID: 38448852 PMC: 10916229. DOI: 10.1186/s12885-024-12027-w.

T* Imaging Assessment of Neoadjuvant Radiation Therapy Combined With Pharmacological Ascorbate in Extremity Soft-Tissue Sarcomas: A Pilot Study.

Lee C, Petronek M, Monga V, Miller B, Milhem M, Magnotta V Iowa Orthop J. 2024; 43(2):60-69.

PMID: 38213860 PMC: 10777695.

Cancer Stem Cells in Sarcomas: In Vitro Isolation and Role as Prognostic Markers: A Systematic Review.

Chico M, Mesas C, Doello K, Quinonero F, Perazzoli G, Ortiz R Cancers (Basel). 2023; 15(9).

PMID: 37173919 PMC: 10177331. DOI: 10.3390/cancers15092449.

References

Le Cesne A, Ouali M, Leahy M, Santoro A, Hoekstra H, Hohenberger P . Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. Ann Oncol. 2014; 25(12):2425-2432. DOI: 10.1093/annonc/mdu460. View

Fong Y, Coit D, Woodruff J, Brennan M . Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg. 1993; 217(1):72-7. PMC: 1242736. DOI: 10.1097/00000658-199301000-00012. View

Issels R, Lindner L, Verweij J, Wust P, Reichardt P, Schem B . Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol. 2010; 11(6):561-70. PMC: 3517819. DOI: 10.1016/S1470-2045(10)70071-1. View

Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M . A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008; 113(3):573-81. DOI: 10.1002/cncr.23592. View

Pisters P, Leung D, Woodruff J, Shi W, Brennan M . Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol. 1996; 14(5):1679-89. DOI: 10.1200/JCO.1996.14.5.1679. View

Patel S, Vadhan-Raj S, Papadopolous N, Plager C, Burgess M, Hays C . High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. J Clin Oncol. 1997; 15(6):2378-84. DOI: 10.1200/JCO.1997.15.6.2378. View

Penel N, Bui B, Bay J, Cupissol D, Ray-Coquard I, Piperno-Neumann S . Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008; 26(32):5269-74. DOI: 10.1200/JCO.2008.17.3146. View

LAWRENCE Jr W, DONEGAN W, Natarajan N, Mettlin C, Beart R, Winchester D . Adult soft tissue sarcomas. A pattern of care survey of the American College of Surgeons. Ann Surg. 1987; 205(4):349-59. PMC: 1492738. DOI: 10.1097/00000658-198704000-00003. View

OSullivan B, Griffin A, Dickie C, Sharpe M, Chung P, Catton C . Phase 2 study of preoperative image-guided intensity-modulated radiation therapy to reduce wound and combined modality morbidities in lower extremity soft tissue sarcoma. Cancer. 2013; 119(10):1878-84. DOI: 10.1002/cncr.27951. View

10.

Lans T, Grunhagen D, de Wilt J, van Geel A, Eggermont A . Isolated limb perfusions with tumor necrosis factor and melphalan for locally recurrent soft tissue sarcoma in previously irradiated limbs. Ann Surg Oncol. 2005; 12(5):406-11. DOI: 10.1245/ASO.2005.03.093. View

11.

Wagner A, Malinowska-Kolodziej I, Morgan J, Qin W, Fletcher C, Vena N . Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol. 2010; 28(5):835-40. PMC: 4810029. DOI: 10.1200/JCO.2009.25.2981. View

12.

Maduekwe U, Hornicek F, Springfield D, Raskin K, Harmon D, Choy E . Role of sentinel lymph node biopsy in the staging of synovial, epithelioid, and clear cell sarcomas. Ann Surg Oncol. 2009; 16(5):1356-63. DOI: 10.1245/s10434-009-0393-9. View

13.

Martin-Liberal J, Alam S, Constantinidou A, Fisher C, Khabra K, Messiou C . Clinical activity and tolerability of a 14-day infusional Ifosfamide schedule in soft-tissue sarcoma. Sarcoma. 2013; 2013:868973. PMC: 3867825. DOI: 10.1155/2013/868973. View

14.

Sleijfer S, Ouali M, Van Glabbeke M, Krarup-Hansen A, Rodenhuis S, Cesne A . Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research.... Eur J Cancer. 2009; 46(1):72-83. DOI: 10.1016/j.ejca.2009.09.022. View

15.

Stacchiotti S, Palassini E, Sanfilippo R, Vincenzi B, Arena M, Bochicchio A . Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network. Ann Oncol. 2011; 23(2):501-8. DOI: 10.1093/annonc/mdr066. View

16.

Levay J, OSullivan B, Catton C, Bell R, Fornasier V, Cummings B . Outcome and prognostic factors in soft tissue sarcoma in the adult. Int J Radiat Oncol Biol Phys. 1993; 27(5):1091-9. DOI: 10.1016/0360-3016(93)90529-5. View

17.

Christie-Large M, James S, Tiessen L, Davies A, Grimer R . Imaging strategy for detecting lung metastases at presentation in patients with soft tissue sarcomas. Eur J Cancer. 2008; 44(13):1841-5. DOI: 10.1016/j.ejca.2008.06.004. View

18.

Burton G, Rankin C, Zalupski M, Mills G, Borden E, Karen A . Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma. Am J Clin Oncol. 2006; 29(1):59-61. DOI: 10.1097/01.coc.0000195088.28956.dd. View

19.

Goldstein D, Cheuvart B, Trump D, Shiraki M, Comis R, Tormey D . Phase II trial of carboplatin in soft-tissue sarcoma. Am J Clin Oncol. 1990; 13(5):420-3. DOI: 10.1097/00000421-199010000-00011. View

20.

Jemal A, Tiwari R, Murray T, Ghafoor A, Samuels A, Ward E . Cancer statistics, 2004. CA Cancer J Clin. 2004; 54(1):8-29. DOI: 10.3322/canjclin.54.1.8. View